Novartis AG (NOVNEE) - Analysis

109.76000 CHF

0.24

0.22%

Last update Dec 30, 4:30 PM CET

Market closed

Day range

109.76000

109.68000

109.98000

Previous close

110

Open

109.70000

Access this stock data via API

Novartis AG

109.76

0.24

0.22%

Analysis

Revenue estimate	Next quarter (Mar 2026)	Next year (Dec 2026)
Number of Analysts	2	16
Avg. estimate	13.96B	56.97B
Low estimate	13.60B	54.19B
High estimate	14.32B	58.67B
Last year sales	13.62B	55.66B
Sales growth	0.02	0.02

Access /revenue_estimate data via our API — starting from the Ultra plan.

EPS revisions	Next quarter (Mar 2026)	Next year (Dec 2026)
Up last 7 days	0	0
Up last 30 days	0	0
Down last 7 days	0	0
Down last 30 days	0	0

Access /eps_revisions data via our API — starting from the Ultra plan.

Analyst ratings

Firm	Date	Action
Morgan Stanley	Sep 25, 2023	Upgrade
Wolfe Research	May 09, 2022	Downgrade
Exane BNP Paribas	Dec 06, 2021	Downgrade
Bryan Garnier	Dec 03, 2021	Downgrade
Deutsche Bank	Sep 20, 2021	Downgrade
Argus Research	Mar 10, 2021	Downgrade
Cowen& Co.	Feb 01, 2021	Downgrade
Cowen & Co.	Feb 01, 2021	Downgrade
Deutsche Bank	Jan 15, 2021	Initiates
Morgan Stanley	Sep 01, 2020	Upgrade
Guggenheim	Feb 25, 2020	Downgrade
Guggenheim Securities	Feb 25, 2020	Downgrade
Guggenheim	Apr 25, 2019	Upgrade
Morgan Stanley	Apr 10, 2019	Downgrade
Cowen & Co.	Nov 26, 2018	Upgrade
Goldman Sachs	Nov 19, 2018	Upgrade
Citigroup	Sep 11, 2018	Upgrade
Bank of America	Sep 10, 2018	Upgrade
B of A Securities	Sep 10, 2018	Upgrade
Barclays	Jul 19, 2018	Upgrade
HSBC	May 29, 2018	Downgrade
Credit Suisse	May 25, 2018	Upgrade
Leerink Swann	Jan 25, 2018	Maintains
Barclays	Oct 25, 2017	Downgrade
Leerink Swann	Oct 23, 2017	Maintains
Morgan Stanley	Jul 26, 2017	Upgrade
Credit Suisse	Jul 05, 2017	Downgrade
Cowen & Co.	Apr 05, 2017	Downgrade
Credit Suisse	Jan 11, 2017	Downgrade
JP Morgan	Jan 03, 2017	Downgrade

Access /analyst_ratings/light data via our API — starting from the Ultra plan.